Schlack W, Schäfer M, Uebing A, Schäfer S, Borchard U, Thämer V
Physiologisches Institut, Abteilung für Herz- und Kreislaufphysiologie, Heinrich-Heine-Universität, Düsseldorf, Germany.
J Cardiovasc Pharmacol. 1993 Jul;22(1):89-96. doi: 10.1097/00005344-199307000-00015.
Reestablishment of blood supply to ischemic myocardium leads to biochemical and cellular changes which are believed to reduce the amount of potentially salvageable myocardium (reperfusion injury). In this situation, adenosine is known to have myocardial protective properties. Activation of adenosine A2-receptors may account for most of the beneficial effects of adenosine in reperfusion injury because A2-receptor activation mediates vasodilation, inhibits neutrophil adhesion to vascular endothelium and diminishes generation of free radicals by neutrophils, thus acting on some of the key mechanisms of reperfusion injury such as postischemic vascular dysfunction and neutrophil-mediated damage. Therefore, we investigated the effect of an intracoronary A2-agonist, CGS 21680, on regional postischemic myocardial function (measured as wall thickening) and infarct size [determined by triphenyltetrazolium chloride (TTC) staining]. Fourteen anesthetized open-chest dogs underwent 1-h left anterior descending artery (LAD) occlusion and 6-h reperfusion and were randomly assigned to receive intracoronary CGS 21680 or to serve as control. The drug was infused for 60 min starting 5 min before reperfusion with a concentration of 10(-7) M at a rate of 10 ml/min under anoxic conditions. The infusion was then continued for the first 55 min of reperfusion with 10(-6) M at a rate of 1 ml/min. Intracoronary infusion of CGS 21680 led to significant improvement in regional wall function in postischemic myocardium (p < 0.05 vs. control). Thickening fraction (percentage of baseline) increased from -13.1 +/- 13.7% (mean +/- SD) during occlusion to 15.3 +/- 29.8% at 30 min of reperfusion in the CGS 21680 treatment group and remained at this level throughout the reperfusion period.(ABSTRACT TRUNCATED AT 250 WORDS)
恢复缺血心肌的血液供应会导致生化和细胞变化,据信这些变化会减少潜在可挽救心肌的数量(再灌注损伤)。在这种情况下,已知腺苷具有心肌保护特性。腺苷A2受体的激活可能是腺苷在再灌注损伤中大部分有益作用的原因,因为A2受体激活介导血管舒张,抑制中性粒细胞与血管内皮的粘附,并减少中性粒细胞产生自由基,从而作用于再灌注损伤的一些关键机制,如缺血后血管功能障碍和中性粒细胞介导的损伤。因此,我们研究了冠状动脉内A2激动剂CGS 21680对局部缺血后心肌功能(以室壁增厚衡量)和梗死面积[通过氯化三苯基四氮唑(TTC)染色确定]的影响。14只麻醉开胸犬接受1小时左前降支动脉(LAD)闭塞和6小时再灌注,并随机分为接受冠状动脉内CGS 21680或作为对照组。在缺氧条件下,于再灌注前5分钟开始以10毫升/分钟的速度输注浓度为10(-7)M的药物60分钟。然后在再灌注的前55分钟以1毫升/分钟的速度继续输注10(-6)M。冠状动脉内输注CGS 21680导致缺血后心肌局部室壁功能显著改善(与对照组相比,p < 0.05)。CGS 21680治疗组的增厚分数(相对于基线的百分比)在闭塞期间从-13.1 +/- 13.7%(平均值 +/- 标准差)增加到再灌注30分钟时的15.3 +/- 29.8%,并在整个再灌注期间保持在该水平。(摘要截短至250字)